Sars-Cov-2 Vaccination Induced Gbs is a Severe Complication of All Types of Vaccines and Requires Prompt and Appropriate Treatment

We read with interest the article by Nagalli et al. about a 49 years-old female who developed lower limb weakness 10 days after the first dose of the mRNA-1274 (Moderna) anti-SARS-CoV-2 vaccine [1]. Muscle weakness progressed to the upper limbs and the respiratory muscles resulting respiratory insufficiency with the need for mechanical ventilation [1]. The patient was diagnosed with SARS-CoV-2 induced Guillain-Barre syndrome (GBS) not earlier than eight weeks after onset of muscle weakness [1]. The patient benefitted from plasmaphereses and reached partial recovery at discharge to a rehabilitation facility [1]. The study is appealing but raises concerns that need to be discussed. We do not agree with the notion that GBS had a “subacute” onset as indicated in the title [1]. Distal lower limb weakness started 10 days after the vaccination, corresponding to an acute onset. We thus also disagree with the speculation in the abstract that the patient could have had chronic inflammatory demyelinating polyneuropathy (CIDP) [1].